trending Market Intelligence /marketintelligence/en/news-insights/trending/8yu42afjbe4h_yw_xvszda2 content esgSubNav
In This List

Hybrigenics completes genomics unit buyout as part of strategic shift

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Hybrigenics completes genomics unit buyout as part of strategic shift

Hybrigenics SA completed the previously announced buyout of its unit Helixio, which provides genomic services, by its employees and managers.

Financial terms of the transaction were not disclosed.

The buyout is part of Hybrigenics' strategic refocusing on biopharmaceutical research and development, particularly on anti-cancer drugs. Following the transaction, the Paris-based company and Helixio will operate as fully independent entities.